Nomogram Model Based on Serum Metabolic Biomarkers to Predict Outcomes of First-Line Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer
Preprint
- 6 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: This study attempted to combine Serum Metabolic Biomarkers with clinical factors to construct nomograms to predict outcomes of patients with advanced non-small cell lung cancer( NSCLC) receiving first-line chemoimmunotherapy (CIT). Methods: A retrospective analysis was conducted on 112 patients with stage IIIC–IVB NSCLC receiving first-line CIT between January 2019 and January 2022.The Serum Metabolic Biomarker including lactate dehydrogenase (LDH), lactate (LAC), uric acid (UA), albumin (ALB), triglycerides (TG) and total cholesterol (TC) were examined at baseline. Patients were stratified into responders (R)and non-responders(NR) based on treatment efficacy. Progression-free survival (PFS) and overall survival (OS) were assessed via Kaplan-Meier analysis. Nomograms was created based on the multivariate Cox regression analysis to predict OS and PFS. The nomogram was internally validated using bootstrap resampling. Nomogram was assessed using the concordance index (C-index), the time-dependent area under the receiver operating curves(ROC), calibration curves, and decision curve analysis (DCA). Results: Non-diabetic status, PD-L1 expression≥50%, low LDH, LAC, UA, TC and high ALB correlated with better response (all PConclusion: Serum metabolic biomarkers (LDH, LAC, UA, ALB, TG) hold significant value in predicting outcomes of chemoimmunotherapy in advanced NSCLC. The nomograms provide accurate and practical tools to guide personalized treatment decisions.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Metabolic regulation of homologous recombination repair by MRE11 lactylationCell, 2023
- Can uric acid affect the immune microenvironment in bladder cancer? A single‐center multi‐omics studyMolecular Carcinogenesis, 2023
- Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancerClinical and Translational Oncology, 2023
- Real world prognostic utility of platelet lymphocyte ratio and nutritional status in first-line immunotherapy response in stage IV non-small cell lung cancerCancer Treatment and Research Communications, 2023
- Changes in serum uric acid, serum uric acid/serum creatinine ratio, and gamma-glutamyltransferase might predict the efficacy of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancerStrahlentherapie und Onkologie, 2023
- Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancerCancer, 2022
- Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironmentsCancer Cell, 2022
- Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-AnalysisJournal of Thoracic Oncology, 2021
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009